Pyridin[3,4-B]pyrazinoner

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R2, R6A, R6B and R8 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and intermediate...

Full description

Saved in:
Bibliographic Details
Main Authors BROWN, DAVID, LOUIS, FOBIAN, YVETTE, MARLENE, MOLYNEAUX, JOHN, MAJOR, PHILLIPS, CHRISTOPHER, JACOBSEN, ERIC, JON, MISCHKE, BRENT, VIRGIL, MADDUX, TODD, MICHAEL, ROGIER, DONALD, JOSEPH, JR, MOON, JOSEPH, BLAIR, TOLLEFSON, MICHAEL, BRENT, BROWN, DAVID, GRAHAM, FRESKOS, JOHN, NICHOLAS, PALMER, MICHAEL, JOHN, HEASLEY, STEVEN, EDWARD, WALKER, JOHN, KEITH, BELL, ANDREW, SIMON, HUGHES, ROBERT, O, OWEN, DAFYDD, RHYS
Format Patent
LanguageDanish
Published 15.08.2011
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R2, R6A, R6B and R8 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and intermediates are also disclosed.
Bibliography:Application Number: DK20070734320T